LSS-11, a novel triazolonaphthalimide-based topoisomerase inhibitor, overcomes paclitaxel-resistance in lung cancer cells via DR5/PARP1-mediated apoptosis and STAT3-mediated downregulation of MDR1 and MRP1. This evidence concerns the gene ABCB1 and lung carcinoma.